ArticleBMC cancer2026
Integrated primary tumor and all metastatic lymph nodes radiomics from 18 F-FDG PET/CT for precise M1 subclassification in nasopharyngeal carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe false-negative rate of approximately 18% in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) can lead to understaging by misclassifying M1b disease as M1a of nasopharyngeal carcinoma (NPC), which may result in the inappropriate administration of intensified therapy. This study aims to develop a 18F-FDG PET/CT-based prediction tool to assist clinicians in diagnosing TNM-9 M1 staging and guiding treatment decisions for patients with synchronous NPC (smNPC).
methodsNinety-seven patients with squamous cell carcinoma smNPC underwent pretreatment 18F-FDG PET/C. Radiomic features were extracted from primary tumors and all metastatic lymph nodes using CT and PET data. Ten metabolic parameters of the primary tumors and most FDG-avid metastatic lymph node, measured through three methods, were also assessed. After feature selection, nine logistic regression-based radiomics models and one random forest model were developed. Model Performance was evaluated via 10 repeats×5-fold cross-validation mean the Area Under the Receiver Operating Characteristic Curve (AUC). The optimal prediction model was presented using a nomogram developed on the entire cohort and was validated with a calibration curve, decision curve analysis (DCA), and by determining its optimal cut-off value.
resultsThe M1a and M1b patient groups showed no significant differences in baseline characteristics or metabolic parameters from the primary tumors and metastatic lymph nodes (p > 0.05). The combined primary tumors and metastatic lymph nodes radiomics model achieved the highest AUC of 0.907 in validation set. The final nomogram demonstrated excellent discrimination (AUC 0.963), with sensitivity of 98.1% and specificity of 86.0% at the optimal cutoff (0.439). Calibration was reliable (slope 0.853, intercept 0.132). DCA confirmed clinical utility, providing net benefit across a wide threshold range (0.135–0.700) with a maximum net benefit of 0.533 at a threshold probability of 0.050.
conclusionThis study offers a complementary diagnostic tool for M1 staging of smNPC that may inform treatment decisions. The findings also provide metabolic evidence supporting the robustness of the TNM-9 stage IV classification system of NPC.
trial registrationThis retrospective study was in accordance with the Declaration of Helsinki and approved by the XXX.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.